Literature DB >> 20662620

Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea.

Kjetil Garborg1, Bjørn Waagsbø, Asbjørn Stallemo, Jon Matre, Anders Sundøy.   

Abstract

We report a success rate of 83% with faecal donor instillation therapy (FDIT) in this retrospective study of 40 patients with recurrent Clostridium difficile-associated diarrhoea (CDAD), treated at a medium sized Norwegian hospital from 1994 through 2008. The stool transplant was instilled either in the duodenum through a gastroscope or in the colon through a colonoscope with next of kin or other household member as donor. In 29 cases (73%) the first treatment was successful, with no documented recurrence of diarrhoeal disease within 80 days. Of the 11 patients failing to respond to the first instillation treatment, 6 patients received a second instillation, 4 of which were successful. A total of 33 patients (83%) were successfully treated with FDIT. Of the 7 non-responders, 5 were seriously ill due to long lasting diarrhoeal disease and co-morbidity and died within 80 days after the procedure, and 2 were believed to have inflammatory bowel disease with response to corticosteroid treatment. No adverse effects of FDIT were observed. In our experience the procedure is easy to perform, well tolerated, effective, and may be a valuable treatment option in selected cases.

Entities:  

Mesh:

Year:  2010        PMID: 20662620     DOI: 10.3109/00365548.2010.499541

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  35 in total

1.  Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Dina Kao; Brandi Roach; Marisela Silva; Paul Beck; Kevin Rioux; Gilaad G Kaplan; Hsiu-Ju Chang; Stephanie Coward; Karen J Goodman; Huiping Xu; Karen Madsen; Andrew Mason; Gane Ka-Shu Wong; Juan Jovel; Jordan Patterson; Thomas Louie
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

Review 2.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 3.  Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis.

Authors:  R Postigo; J H Kim
Journal:  Infection       Date:  2012-07-31       Impact factor: 3.553

Review 4.  Restoring the gut microbiome for the treatment of inflammatory bowel diseases.

Authors:  Jessica R Allegretti; Matthew J Hamilton
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

5.  Fecal microbiota transplant for Clostridium difficile infection in older adults.

Authors:  William M Tauxe; John P Haydek; Paulina A Rebolledo; Emma Neish; Kira L Newman; Angela Ward; Tanvi Dhere; Colleen S Kraft
Journal:  Therap Adv Gastroenterol       Date:  2015-12-31       Impact factor: 4.409

6.  Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Fred A Anderson; Heena P Santry
Journal:  J Gastrointest Surg       Date:  2014-11-19       Impact factor: 3.452

Review 7.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

8.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 9.  Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.

Authors:  Marie Céline Zanella Terrier; Martine Louis Simonet; Philippe Bichard; Jean Louis Frossard
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  The role of the microbiome in rheumatic diseases.

Authors:  Nigel Yeoh; Jeremy P Burton; Praema Suppiah; Gregor Reid; Simon Stebbings
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.